JPMorgan analyst Benjamin Rossi assumed coverage of Concentra (CON) with an Overweight rating and unchanged $31 price target The firm views current outpatient environment to be most favorable for companies with lower reimbursement exposure to federal funding. Concentra is the analyst’s top pick among outpatient names given the company’s lower exposure to federal spending programs.
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CON:
- Concentra Group Holdings: Strong Q2 Results and Raised 2025 EBITDA Guidance Support Buy Rating
- Concentra Group Reports Strong Q2 2025 Results
- Concentra Group Reports Strong Q2 2025 Financial Results
- Concentra reports 2Q adjusted EPS 37c, consensus 38c
- Concentra sees FY25 revenue $2.13B-$2.16B, consensus $2.13B